Actimed Therapeutics Continues to Strengthen Intellectual Property Portfolio with Newly Granted US and Canadian Patents
London, UK – 13 October, 2021. Actimed Therapeutics Ltd, the clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, announces that it has been granted a United States patent for ACM-001 (S-pindolol) for treating muscle weakness and a Canadian patent for ACM-002 (S-oxprenolol) for treating amyotrophic lateral sclerosis (ALS).
The first of these new patents (US 11,096,908) extends the protection of Actimed in the US for S-pindolol to a different indication, namely acute muscle weakness caused by musculoskeletal injury. This new intellectual property protection for treating injury-induced muscle weakness in the US will strengthen the Actimed global intellectual property portfolio around its lead asset, with the potential to address a new indication in the world’s largest pharmaceutical market.
The new Canadian patent for treating ALS with S-oxprenolol (CA 2 906 206) follows from granted US and European patents to Actimed relating to S-oxprenolol for the treatment of ALS. S-oxprenolol is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed and this newest patent completes the global patent estate relating to the treatment of ALS with S-oxprenolol. Actimed has retained global rights to S-oxprenolol in ALS, where loss of body mass and muscle wasting can impact survival. The global rights to S-oxprenolol in cancer cachexia were out licensed to Faraday early this year.
Robin Bhattacherjee, Actimed CEO, commented: “We are very pleased to confirm the grant of these two new patents relating to S-pindolol and S-oxprenolol in the US and Canada respectively. We are committed to broadening our global patent estate as we continue to extend our internal pipeline opportunities and seek to provide access to innovative treatments across multiple indications. Having these most recent patents awarded, particularly for S-pindolol for a new indication in the US, is important as it provides us with an expanded platform for development opportunities and potentially to extend our partnering efforts.”